ARS Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
SPRY$2.79+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value and share amounts)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $70,971 | $210,518 |
| Short-term investments | 157,389 | 63,863 |
| Prepaid expenses and other current assets | 3,366 | 3,319 |
| Total current assets | 231,726 | 277,700 |
| Right-of-use asset | 250 | 445 |
| Fixed assets, net | 574 | 329 |
| Other assets | 638 | 2,961 |
| Total assets | $233,188 | $281,435 |
| Liabilities, convertible preferred stock and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (including related party amounts of $178 and $16, respectively) | $2,154 | $4,931 |
| Lease liability, current | 237 | 230 |
| Contract liability, current | — | 283 |
| Total current liabilities | 2,391 | 5,444 |
| Lease liability, net of current portion | 37 | 251 |
| Contract liability, net of current portion | — | 2,854 |
| Total liabilities | 2,428 | 8,549 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized at December 31, 2023 and 2022; 96,414,963 and 93,943,316 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 10 | 9 |
| Additional paid-in capital | 362,004 | 349,408 |
| Accumulated other comprehensive gain, net | 49 | 407 |
| Accumulated deficit | (131,303) | (76,938) |
| Total stockholders’ equity | 230,760 | 272,886 |
| Total liabilities, convertible preferred stock and stockholders’ equity | $233,188 | $281,435 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.